GLP-1 receptor agonists, particularly new generation agents such as semaglutide and tirzepatide, may significantly reduce the risk for arthroplasty in patients with knee osteoarthritis, data show.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results